NECTAR LIFESCIENCES
|
NECTAR LIFESCIENCES Last 5 Year Financial Ratios History
[Consolidated]
| Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 0.22 | -1.08 | 1.12 | -3.27 | 1.44 |
| CEPS(Rs) | 2.93 | 1.56 | 3.66 | -0.58 | 4.13 |
| DPS(Rs) | - | - | - | - | 0.05 |
| Book NAV/Share(Rs) | 47.68 | 47.47 | 48.51 | 47.36 | 50.66 |
| Tax Rate(%) | 72.66 | 42.99 | 26.51 | 13.57 | 15.16 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 7.87 | 3.03 | 8.23 | 5.75 | 8.31 |
| EBIT Margin(%) | 5.98 | 2.69 | 5.86 | 1.55 | 6.18 |
| Pre Tax Margin(%) | 0.95 | -2.43 | 1.77 | -4.81 | 1.42 |
| PAT Margin (%) | 0.26 | -1.38 | 1.30 | -4.15 | 1.20 |
| Cash Profit Margin (%) | 3.41 | 2.00 | 4.26 | -0.74 | 3.50 |
| Performance Ratios | |||||
| ROA(%) | 0.23 | -1.06 | 1.05 | -2.93 | 1.19 |
| ROE(%) | 0.47 | -2.25 | 2.33 | -6.67 | 2.84 |
| ROCE(%) | 6.54 | 2.49 | 5.77 | 1.41 | 8.32 |
| Asset Turnover(x) | 0.88 | 0.77 | 0.81 | 0.70 | 0.99 |
| Sales/Fixed Asset(x) | 1.22 | 1.12 | 1.23 | 1.15 | 1.76 |
| Working Capital/Sales(x) | 6.19 | 5.13 | 5.49 | 34.29 | 7.20 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.82 | 0.89 | 0.81 | 0.87 | 0.57 |
| Receivable days | 62.43 | 75.92 | 77.89 | 79.75 | 65.92 |
| Inventory Days | 130.94 | 139.23 | 118.26 | 161.98 | 130.89 |
| Payable days | 112.09 | 109.47 | 107.25 | 137.11 | 99.25 |
| Valuation Parameters | |||||
| PER(x) | 135.20 | - | 21.53 | - | 6.86 |
| PCE(x) | 10.28 | 10.18 | 6.58 | -32.06 | 2.40 |
| Price/Book(x) | 0.63 | 0.33 | 0.50 | 0.39 | 0.20 |
| Yield(%) | - | - | - | - | 0.51 |
| EV/Net Sales(x) | 0.77 | 0.72 | 0.83 | 0.84 | 0.41 |
| EV/Core EBITDA(x) | 7.34 | 10.29 | 8.13 | 11.48 | 4.37 |
| EV/EBIT(x) | 11.21 | 23.26 | 12.24 | 47.49 | 6.00 |
| EV/CE(x) | 0.76 | 0.60 | 0.58 | 0.55 | 0.37 |
| M Cap / Sales | 0.40 | 0.23 | 0.32 | 0.27 | 0.09 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 10.53 | -8.70 | 8.13 | -34.78 | -14.97 |
| Core EBITDA Growth(%) | 65.82 | -37.56 | 50.54 | -49.64 | -17.08 |
| EBIT Growth(%) | 145.31 | -58.42 | 314.00 | -83.30 | -21.10 |
| PAT Growth(%) | 120.66 | -196.55 | 134.19 | -330.47 | -33.22 |
| EPS Growth(%) | 120.65 | -196.55 | 134.19 | -326.70 | -32.11 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.59 | 0.71 | 0.79 | 0.85 | 0.69 |
| Current Ratio(x) | 1.32 | 1.38 | 1.35 | 1.04 | 1.29 |
| Quick Ratio(x) | 0.59 | 0.63 | 0.69 | 0.55 | 0.51 |
| Interest Cover(x) | 1.19 | 0.53 | 1.43 | 0.24 | 1.30 |
| Total Debt/Mcap(x) | 0.94 | 2.12 | 1.59 | 2.17 | 3.51 |
Compare Financial Ratios of peers of NECTAR LIFESCIENCES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| NECTAR LIFESCIENCES | ₹782.6 Cr | -1.1% | -6.3% | 40.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹425,930.0 Cr | -1.4% | -7.1% | 48% | Stock Analytics | |
| DIVIS LABORATORIES | ₹156,524.0 Cr | 1.5% | -2.1% | 63% | Stock Analytics | |
| CIPLA | ₹118,828.0 Cr | -3.5% | -5.2% | 18% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹101,290.0 Cr | -3.9% | -10.1% | 10.1% | Stock Analytics | |
| ZYDUS LIFESCIENCES | ₹95,280.3 Cr | -0.3% | -7.3% | 52.2% | Stock Analytics | |
NECTAR LIFESCIENCES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| NECTAR LIFESCIENCES | -1.1% |
-6.3% |
40.1% |
| SENSEX | -2.4% |
-4.2% |
19.5% |
You may also like the below Video Courses
